News Releases

Webcast Johnson & Johnson Third Quarter 2014 Earnings Meeting and Webcast
October 14, 2014
8:30 AM ET

All Releases
View Summary Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate
Nov 19, 2014
PDF 20.8 KB Add to Briefcase
View Summary Real-World Data Presented at the American Heart Association (AHA) Scientific Sessions Underscore Hospitalization and Outpatient Cost-Savings for XARELTO® Compared to Standard of Care
Nov 18, 2014
PDF 24.8 KB Add to Briefcase
View Summary U.S. FDA Approves Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) for the Treatment of Schizoaffective Disorder
Nov 13, 2014
PDF 69.5 KB Add to Briefcase
View Summary Johnson & Johnson Announces Completion Of Alios BioPharma Acquisition
Nov 7, 2014
PDF 8.5 KB Add to Briefcase
View Summary Janssen Highlights its Hepatitis C Clinical Development Program in Advance of 2014 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Nov 7, 2014
PDF 17.1 KB Add to Briefcase
View Summary Janssen to Demonstrate Breadth of Oncology Portfolio with 42 Clinical Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting
Nov 6, 2014
PDF 78.7 KB Add to Briefcase
View Summary OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection
Nov 5, 2014
PDF 26.0 KB Add to Briefcase
View Summary AstraZeneca, Pharmacyclics And Janssen Partner On Immuno-Oncology Combination Trials With IMBRUVICA® For Hematologic Cancers
Nov 4, 2014
PDF 70.0 KB Add to Briefcase
View Summary Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production
Oct 22, 2014
PDF 12.0 KB Add to Briefcase
View Summary IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenström's macroglobulinemia
Oct 20, 2014
PDF 67.5 KB Add to Briefcase
View Summary European Commission Approves IMBRUVICATM in Two Forms of Blood Cancer
Oct 17, 2014
PDF 69.9 KB Add to Briefcase
View Summary Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2014
Oct 16, 2014
PDF 5.6 KB Add to Briefcase
View Summary Johnson & Johnson Reports 2014 Third-Quarter Results:
Oct 14, 2014
PDF 65.1 KB Add to Briefcase
View Summary Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma
Oct 13, 2014
PDF 22.2 KB Add to Briefcase
View Summary Janssen Demonstrates Continued Commitment to Combating Hepatitis C in European Patients with Data Presented at Viral Hepatitis Congress
Oct 10, 2014
PDF 49.0 KB Add to Briefcase
View Summary Janssen Submits Application Seeking Approval Of STELARA® In European Union For Pediatric Plaque Psoriasis
Oct 10, 2014
PDF 16.9 KB Add to Briefcase
View Summary New Findings From The Psoriasis Longitudinal Assessment And Registry (PSOLAR)
Oct 9, 2014
PDF 16.3 KB Add to Briefcase
View Summary Johnson & Johnson Announces Agreement To Acquire Alios BioPharma
Sep 30, 2014
PDF 9.1 KB Add to Briefcase
View Summary CHMP Announces Positive Opinion For REZOLSTA, A New Once-Daily, Fixed-Dose HIV Therapy Combining Darunavir And Cobicistat
Sep 29, 2014
PDF 12.6 KB Add to Briefcase
View Summary ZYTIGA® Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer
Sep 28, 2014
PDF 17.7 KB Add to Briefcase

= add release to Briefcase